The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Ventures Partners and LIOF.

Proceeds will be used to fund a Randomized Controlled Trial for Mediclose, as well as clinical validation of the fully integrated Laprixa System. “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch” said John Marugg, Chief Executive Officer of Corporis Medical.